IMPACT OF TACROLIMUS BLOOD CONCENTRATION ON CLINICAL OUTCOMES IN PATIENTS WITH MYASTHENIA GRAVIS

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HPS-137
• By: YAMAMOTO, Shota (Kyoto University Hospital, Department of Clinical Pharmacology and Therapeutics, Japan)
• Co-author(s): Shota Yamamoto: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Atsushi Yonezawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Yuri Irachi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Ikumi Hirozumi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Yoshiki Katada: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Shunsaku Nakagawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Mitsuhiro Sugimoto: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Yuko Yoshida: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Tomohiro Omura: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  Etsuro Nakanishi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
  Ryosuke Takahashi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
  Kazuo Matsubara: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  
• Abstract:

  Background

  Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies acting primarily against acetylcholine receptors (AChRs), and needs the high-dose and long-continued therapy with prednisolone (PSL) for its treatment. In the clinical practice guideline for MG, it has been described that introduction of tacrolimus (TAC) at early..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login